Navigation Links
Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Date:10/31/2013

262.7)(303.0)Restructuring & other special items

(9.6)(18.7)(26.8)(50.8)Adjusted cost of sales

$

864.2$

861.3$

2,566.7$

2,553.5Adjusted gross profit (a)

$

903.2$

940.5$

2,533.9$

2,519.8Adjusted gross margin (a)

51

%52

%50

%50

%Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012GAAP total operating expenses$

468.7$

458.4$

1,382.1$

1,319.3Deduct:Litigation settlements, net

5.5(8.0)(3.3)2.1Acquisition related costs

(6.3)—(24.8)—Restructuring & other special items

(26.3)(22.5)(78.7)(80.6)Adjusted total operating expenses

$

441.6$

427.9$

1,275.3$

1,240.8Adjusted earnings from operations (b)

$

461.6$

512.6$

1,258.6$

1,279.0Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012GAAP interest expense$

74.0$

76.1$

233.7$

234.1Deduct:Interest expense related to clean energy investment (c)

(1.9)(1.0)(6.0)(3.9)Non-cash accretion of contingent consideration liability

(8.2)(8.3)(23.9)(24.0)Non-cash interest, primarily amortization of convertible debt discount

(7.6)(5.8)(20.1)(23.3)Adjusted interest expense

$

56.3$

61.0$

183.7$

182.9Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012GAAP other income (expense)$

(70.6)$

6.2$

(74.4)$

0.6Add:Clean energy investment operating results (c)

5.24.613.112.3Acquisition related costs

3.4—5.1—Financing related costs

63.9—72.6—Restructuring & other special items

16.4—20.71.3Adjusted other income (expense)

$

18.3$

10.8$


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
2. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
3. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
6. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
7. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
8. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
9. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
10. Roger Graham Named President of Mylan Specialty
11. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... pipeline and new product development efforts. In the second ... Phase 2a study of AZ-002 (Staccato ® ... of patients with acute repetitive seizures.  Additionally, Alexza ... candidates for development - AZ-008 and AZ-009 - ...
(Date:7/31/2014)... Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... development of its lead molecule, Anatabine Citrate, in ... Quotient Clinical, The Translational Pharmaceutics Company, based in the ... its early development programs. The Company expects ... end of the third quarter with the Medicines Healthcare ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... 11, 2011 General Dynamics Information Technology, a ... GD ), has been awarded a contract to ... into the Vincennes University hospital simulation laboratory in ... environment for the continuing education of healthcare professionals ...
... 2011 Medical Insight, Inc. , a progressive media ... debut THE Asian Aesthetic Guide ™ ... in Seoul, Korea. This new publication, directed toward aesthetic physicians, ... THE Asian Aesthetic Guide , available in ...
Cached Medicine Technology:General Dynamics' InForce™ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2Medical Insight to Launch THE Asian Aesthetic Guide at World Congress of Dermatology 2Medical Insight to Launch THE Asian Aesthetic Guide at World Congress of Dermatology 3
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Register to ... one of the most active years on record for life ... in life sciences represented 22 percent of all venture dollars ... exits and achieved high valuations. , However, 2014 is ... a recent report by Silicon Valley Bank, while life sciences ...
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
(Date:7/31/2014)... The 2013 PolyU TSI hit ... from 75.07 in 2012. The index measures inbound ... integrates them into an overall index. The 2013 ... satisfied with Hong Kong over time. , The ... service performance in Hong Kong are attractions (79.27) ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... At the end of a 10-year, coast-to-coast study of women ... Jr., M.D., and three fellow researchers are making the case ... in their tracks. In the August 2009 issue of ... professor of surgery at Dartmouth Medical School (DMS), and his ...
... Texas Health Science Center at Houston has been awarded a ... a center to conduct innovative cancer research. The center will ... funds totaling $11.6 million over a 5-year period. The new ... The CTO is one of the first 12 Physical Sciences-Oncology ...
... interventional radiologist one Friday night three years ago when he ... Hospital & Clinics. He was asked to attend to a ... to the emergency room with massive blood clots in her ... what happened," said Kuo, assistant professor of radiology at the ...
... all products tested contained lead and some had known skin ... little goblins or vampires are set to paint their faces ... want to think twice, according to a new report released ... by the Campaign for Safe Cosmetics, is titled: Pretty ...
... Oct. 27 Dr. Lawrence Brown of Philadelphia, Pennsylvania has ... national nonprofit organization advocating for children and adolescents with neurologic ... three years. Dr. Brown works for Children,s Hospital of ... 2006. , Dr. Brown,s first order of business will be ...
... Life Extension® the global authority on nutrition, ... of scientific information on anti-aging supplements and therapies, ... with 50 mg of Setria® Glutathione from Kyowa ... available from Life Extension® in 100 count bottles ...
Cached Medicine News:Health News:UT leads collaborative initiative for innovative cancer research 2Health News:UT leads collaborative initiative for innovative cancer research 3Health News:UT leads collaborative initiative for innovative cancer research 4Health News:Stanford study recommends change in treating pulmonary embolisms 2Health News:Stanford study recommends change in treating pulmonary embolisms 3Health News:Stanford study recommends change in treating pulmonary embolisms 4Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Dr. Lawrence Brown Named President of the Child Neurology Foundation 2Health News:Life Extension(R) Introduces Glutathione, Cysteine & C Formulation With Setria(R) From Kyowa Hakko USA 2
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
The new Medpor Superior Lateral Orbital Rim is designed for subtle augmentation of the lateral and superior or orbital rims in patients who are hypoplasic in the superior-lateral aspect of the orbita...
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
1.5 mm inner cutting edge....
Medicine Products: